Haemonetics (HAE) Stock: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$104.37
-0.93 (-0.88%)
âŧ
5d:
-1.54%
30d:
+2.37%
90d:
+39.03%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HAE is fairly priced but lacks strong directional signals. At 11.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HAE is fairly priced but lacks strong directional signals. At 11.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$98.18
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$60.96
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $104.37, which is considered fair relative to its 30-day fair value range of $103.06 to $107.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 19.9) compared to its historical average (14.2). At these levels, the market is pricing in 11.9% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is currently testing key support at $103.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HAE scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is currently testing key support at $103.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HAE scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$103.06 -
$107.45
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
40.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($111.50)
- BEARISH: Market expects 11.9% growth - appears too optimistic based on history
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$103.06 -
$107.45
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$103.51
Resistance Level
$110.45
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.90
Wall Street Target
$111.50
(+5.9%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
2.9%
Profit Margin
7.1%
Valuation Premium vs History
+11.9% premium
PE vs Historical
19.9 vs 14.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.9%
(market-implied from PE analysis)
1-Year Target
$117.83
(+12%)
2-Year Target
$131.85
(+25%)
3-Year Target
$147.54
(+40%)
3-Yr Target (if PE normalizes)
(PE: 20â14)
PE COMPRESSION
$105.28
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 7.0%)
$132.39
(+26%)
Base:
(SPY PE: 19.9, Growth: 7.0%)
$129.15
(+23%)
Bear:
(PE: 14.2, Growth: 7.0%)
$92.16
(-13%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Forward PE: 20.33 | Forward EPS (Implied): $5.18
Bull Case
$127.15
(+21%)
Analyst growth 15.0%, PE expands to 21.3
Base Case
$105.30
(0%)
Market implied 0.0%, PE stable at 20.3
Bear Case
$80.55
(-24%)
Severe decline -15.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 01, 2026 4:35 PM ET
Data refreshes hourly during market hours. Next update: 5:35 PM
Data refreshes hourly during market hours. Next update: 5:35 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 57 HOLD |
